2,3-trimethylene-4-quinazolone and Lung Neoplasms

2,3-trimethylene-4-quinazolone has been researched along with Lung Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chatterjee, E; Dhingra, A; Grewal, AS; Guru, SK; Lee, SB; Liou, JP; Mathew, J; Nepali, K; Pan, CH; Rao, NV; Sharma, R; Sharma, S	1

Other Studies

1 other study(ies) available for 2,3-trimethylene-4-quinazolone and Lung Neoplasms

Article	Year
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. European journal of medicinal chemistry, 2022, Oct-05, Volume: 240 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Nanoparticle Drug Delivery System; Quinazolines; Quinazolinones	2022

Article

Year

Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.

European journal of medicinal chemistry, 2022, Oct-05, Volume: 240

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Nanoparticle Drug Delivery System; Quinazolines; Quinazolinones

2022